Company intelligence / Profile preview

Lentechs

Columbus, Ohio, United States

Ownership: Private
Employees: ~9
Development stage: Clinical

Overview

Preliminary clinical trial results show that the APIOC lens provides improved distance vision compared to habitual multifocal contact lenses and comparable performance to prescription glasses for presbyopic patients. The company has completed initial human studies and plans further randomized controlled trials against leading multifocal contact lenses.

Therapeutic areas: Ophthalmology
Modalities: Device (Contact lens)Medical device
Industry: Assistive Medical Devices

Drug pipeline

2 assets

APIOC for Presbyopia

Clinical

Indications: Presbyopia

1 more asset in the full pipeline.

Request access →

Partnerships

Technology licensed from The Ohio State Innovation Foundationpartnerships/support from leading optometric and ophthalmic practitioners

Beyond the preview

Go deeper on Lentechs.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lentechs.

Explore the full profile